The discovery of anti-VEGF drugs has revolutionized the
management of age-related macular degeneration (AMD), diabetic macular edema
(DME) and retinal vein occlusion (RVO). We look back to almost ten years of
anti-VEGF experience in ophthalmology and remain very optimistic about the
therapeutic yield in medical conditions that, before the anti-VEGF era, had a
poor long-term prognosis.
At those times, where photodynamic therapy in
combination with verteporfin was the only principled approach in AMD
management, ophthalmologists had usually bad news for their patients and
actually accompanied them to the state of complete loss of central vision.
Today patients are promised a clear treatment response if
anti- VEGF medications are provided timely. A network meta-analysis, comparing
the two currently licensed drugs Ranibizumab (Lucentis®) and Aflibercept
(Eylea®) against placebo, showed that the benefits for all relevant efficacy
outcomes were consistently positive. Read More.....
No comments:
Post a Comment